Product logins

Find logins to all Clarivate products below.


Parkinson’s Disease – Epidemiology – Extrapolated Worldwide Coverage

Clarivate’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key Parkinson’s disease patient populations covering 171 countries and more than 99% of the global population, delivered in an interactive dashboard-style download.

Use the Extrapolated Worldwide Coverage dashboard to do the following:

  • View 10-year forecasts of the total prevalent cases for all 171 countries, stratified by region and World Bank income status.
  • Aggregate country-level estimates into region-level estimates, according to user preference or as required by regulators for orphan drug designations.
  • Visualize global correlations between disease risk or patient population size and key indicators of market opportunity such as GDP per capita and healthcare spend per capita.
  • Generate and export global heat maps of disease risk or patient population size.

The Extrapolated Worldwide Coverage dashboard is available as an Excel file in the “Downloads” section. It is available for purchase by clients who subscribe to all 45 countries covered by Clarivate Epidemiology. For subscription and entitlement queries, please contact healthcare.support@clarivate.com.

Related Market Assessment Reports

Report
Alzheimer’s Disease – Current Treatment – Treatment Algorithms: Claims Data Analysis – Alzheimer’s Disease (US)
The treatment of early Alzheimer’s disease (AD) is being transformed by the launches of Eisai / Biogen’s lecanemab (Leqembi) and Eli Lilly’s donanemab (Kisunla), and additional disease-…
Report
Parkinson’s Disease – Current Treatment – Treatment Algorithms: Claims Data Analysis – Parkinson’s Disease (US)
Parkinson’s disease (PD) is a progressive neurodegenerative condition that is treated chronically with prescription therapies from an array of mechanistically distinct drug classes, including…
Report
Alzheimer’s Disease – Landscape & Forecast – Disease Landscape & Forecast (G7)
Eisai / Biogen’s lecanemab (Leqembi) and Eli Lilly’s Kisunla (donanemab) have launched for the treatment of early Alzheimer’s disease (AD) in the United States and Japan and, after early…
Report
Multiple Sclerosis – Landscape & Forecast – Disease Landscape & Forecast (G7)
The market for multiple sclerosis (MS) disease-modifying therapies (DMTs) is crowded and competitive, as TG Therapeutics / Neuraxpharm’s Briumvi (ublituximab), Novartis’s Kesimpta (ofatumumab…
Report
Myasthenia Gravis – Current Treatment – Treatment Algorithms: Claims Data Analysis – Myasthenia Gravis (US)
Myasthenia gravis (MG) is a rare neuromuscular disorder caused by autoantibodies at the neuromuscular junction. It leads to fluctuating muscle weakness and fatigue. Standard treatments include…